The Pathway from Skin to Liver: Psoriasis
DOI:
https://doi.org/10.66588/NCMR.v3i1.4Anahtar Kelimeler:
Skin- Inflammation- Non-alcoholic fatty liver disease- PsoriasisÖz
Psoriasis is a chronic, recurrent, autoimmune, inflammatory skin disease. While psoriasis was considered limited to the skin in the past, it is now recognized as a chronic systemic inflammatory disease accompanied by many comorbidities. The main comorbidities of the disease are non-alcoholic fatty liver disease (NAFLD), mood disorders including depression, cardiometabolic diseases including myocardial infarction, hypertension, type 2 diabetes mellitus, hyperuricemia, dyslipidemia, obesity, metabolic syndrome, and psoriatic arthritis. NAFLD is estimated to have a prevalence of 25% in the general population and is a leading cause of cirrhosis and liver transplantation. Currently, NAFLD has become an escalating epidemic, driven by the rising incidence of obesity, metabolic syndrome, and insulin resistance, as well as the systemic effects of psoriasis itself. This review aims to highlight the adverse effects of psoriasis, a skin disease requiring long-term medication, on the liver, and to emphasize these effects when planning treatment regimens.
İndirmeler
Referanslar
Atakan N, Doğan S. Psoriasis, a systemic disease? Turk J Dermatol. 2012;6(3):119-22. https://doi.org/10.5152/tdd.2012.27
Doğan S, Menteşoğlu D, Atakan N, Şimşek H. A cross-sectional study investigating association of liver diseases in moderate to severe psoriasis patients. Turkderm-Turk Arch Dermatol Venereology 2019;53:15-8. https://doi.org/10.4274/turkderm.galenos.2018.82085
Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med. Sci 2018;33(1):173-180. https://doi.org/10.1007/s10103-017-2360-1
Kalkan G. Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management. Review. Turkderm-Turk Arch Dermatol Venereology 2017;51:71-7. https://doi.org/10.4274/-turkderm.09476
Balak DMW, Piaserico S, Kasujee I. Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with psoriasis: a review of the hepatic effects of systemic therapies. Review. Psoriasis: Targets and Therapy 2021;11: 151-168. https://doi.org/10.2147/PTT.S342911
Belinchón-Romero I, Bellot P, Romero-Pérez D, Herraiz-Romero I, Marco F, Frances R, et al. Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. Sci Rep. 2021;21:11(1):8593. https://doi.org/10.1038/s41598-021-88043-8
Munera-Campos M, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, et al. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. J Dermatolog Treat. 2022;33(4):2110-2117. https://doi.org/10.1080/09546634.2021.1922572
Ogdie A, Grewal SK, Noe MH, Shin DB, Takeshita J, Chiesa Fuxench ZC. et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. Journal of Investigative Dermatology 2018;138(4):760-767. https://doi.org/10.1016/j.jid.2017.10.024
Heitmann J, Frings VG, Geier A, Goebeler M, Kerstan A. Non-alcoholic fatty liver disease and psoriasis- is there a shared proinflammatory network? Review. J Dtsch Dermatol Ges. 2021;19(4):517-528. https://doi.org/10.1111/ddg.14425
Klujszo EH, Parcheta P, Witkowska AB, Krecisz B. Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications. Review. Postepy Dermatol Alergol. 2020;37(4):468-474. https://doi.org/-10.5114/ada.2019.83983
Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Review Article. Br J Dermatol. 2018;179(1):16-29. https://doi.org/-10.1111/bjd.16239
Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: so far, so near. World J Hepatol. 2015;7(3):315-326. https://doi.org/10.4254/wjh.v7.i3.315
Olveira A, Augustin S, Benlloch S, Ampuero J, Suárez-Pérez JA, Armesto S, et al. The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease. Life (Basel). 2023;13(2):419. https://doi.org/10.3390/life13020419
Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009; 51(4):758-764. https://doi.org/10.1016/j.jhep.2009.04.020
Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver illness and psoriatic patients. Review Article. BioMed Res Int. 2018;3140983. https://doi.org/10.1155/2018/3140983
Yayınlanmış
Sayı
Bölüm
Kategoriler
Nasıl Atıf Yapılır
